Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neptune Wellness Solutions Inc NEPTF

Neptune Wellness Solutions Inc. is a consumer-packaged goods company that is primarily focused on health and wellness products. The Company focuses on developing a portfolio of consumer products that align with the market trends for natural, sustainable, plant-based, and purpose-driven lifestyle brands. Its products are available in more than 29,000 retail locations and include organic food and beverage brands, such as Sprout Organics, Nosh, and Nurturme, as well as nutraceuticals brands like Biodroga and Forest Remedies. Its main brand units are nutraceuticals and organic foods and beverages. The Company sells its nutraceutical products mainly in bulk soft gels or liquids to multiple distributors and customers, who commercialize these products under their private label. The Company, through its Sprout subsidiary, sells its organic foods and beverages products to mass retailers, grocery stores and other retail outlets, as well as online through e-commerce sites and its own Website.


OTCPK:NEPTF - Post by User

Post by Francine01on Nov 17, 2017 11:48am
105 Views
Post# 26984385

Acasti amended prospectus for 11,700,000 shares

Acasti amended prospectus for 11,700,000 sharesAcasti amended is prospectus and specified 11,700,000 share. 

Doing the math with 25,000,000 shares, Neptune would fall under the 20% ownership and avoid consolidation of R&D losses.

Since all the potential of Acasti and proably get some phase 3 results in 2018, I am not sure if a dillution for Neptune  is a good news with all the cash that Neptune have. 

Best option for Acasti, would be to be purchase by a major pharma just before end of phase 3, so Neptune shareholders will cash.

Any thoughts on this ? 
Bullboard Posts